by Richard Daverman, PhD
February 25, 2013 -- China Grand Pharmaceutical and Healthcare will form a JV with HuangShi Feiyun Pharma that will be capitalized with $20 million. China Grand Pharma will contribute $12 million while HuangShi Feiyun will purchase the remaining 40% with $8 million. HuangShi Feiyun is an oncology drug and anti-viral medicines company located in Hubei Province. Its products will be the basis of the new JV and will serve to expand China Grand Pharma’s portfolio. More details....
Stock Symbol: (HK: 00512)
